Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.

Abstract:

:The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-deoxy-d-glucose (FDG)-PET scan was performed after four cycles (PET-4), on completion of chemotherapy after 6/8 cycles (PET-6/8) and 3 months after the completion of chemotherapy (PET 3-months). Median follow-up was 55 months. The negative predictive value (NPV) for PET-4, PET-6/8 and PET 3-months was 98%, 95% and 97%, respectively. The 4-year progression-free survival (PFS) for PET-4 negative (n = 51) and PET-4 positive (n = 18) patients was 96% and 78%, respectively (p = 0.016). The 4-year PFS for PET-6/8 negative (n = 59) and PET-6/8 positive (n = 9) patients was 95% and 78%, respectively (p = 0.046). Patients with a large mediastinal mass constituted nearly all of the PET-4 positive (16/18) and PET-6/8 positive (8/9) patients. After radiotherapy of PET-6/8 positive patients, PET 3-months was negative in 64 (97%) and positive in two (3%) patients. PET 3-months after the end of chemotherapy was of limited value when the interim PET-4 was negative. Interim PET after four cycles of bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) is a strong prognostic marker for PFS in advanced HL.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Markova J,Kahraman D,Kobe C,Skopalova M,Mocikova H,Klaskova K,Dedeckova K,Eich HT,Böll B,Dietlein M,Kozak T

doi

10.3109/10428194.2011.603444

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

64-70

issue

1

eissn

1042-8194

issn

1029-2403

journal_volume

53

pub_type

杂志文章
  • Case 36: a difficult diagnosis in a patient with fever and progressive multi-organ failure.

    abstract::A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701342703

    authors: Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

    更新日期:2007-07-01 00:00:00

  • Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

    abstract::FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802709438

    authors: Liu H,Li H,Feng Z,Tai J,Meng Y,Wang H,Xin H,Zhang S,Zuo M,Zhang Y,Chen X

    更新日期:2009-03-01 00:00:00

  • Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

    abstract::Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without significant treatment-related mortality (TRM), is particularly appealing in AML with favorable genetic/molecular profile. This study retrospectively evaluated the outcomes of post-remission treatment in consecutive favorable-risk A...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1594214

    authors: Beyar-Katz O,Lavi N,Ringelstein-Harlev S,Henig I,Yehudai-Ofir D,Haddad N,Fineman R,Ofran Y,Nov Y,Sahar D,Moustafa-Hawash N,Rowe JM,Zuckerman T

    更新日期:2019-10-01 00:00:00

  • Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.

    abstract::Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903406798

    authors: Fung KL,Liang RH,Chan GC

    更新日期:2010-03-01 00:00:00

  • Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation.

    abstract::Human herpes virus type 6 can reactivate in patients after allogeneic stem cell transplantation and has been associated with serious sequelae such as delayed engraftment and an increased risk of developing acute graft-versus-host disease (GVHD). This study investigated human herpes virus type 6 (HHV-6) reactivation wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2016.1157873

    authors: Cirrone F,Ippoliti C,Wang H,Zhou XK,Gergis U,Mayer S,Shore T,van Besien K

    更新日期:2016-11-01 00:00:00

  • Study of specific genetic and epigenetic variables in multiple myeloma.

    abstract::Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.528095

    authors: Hatzimichael E,Dasoula A,Benetatos L,Syed N,Dranitsaris G,Crook T,Bourantas K

    更新日期:2010-12-01 00:00:00

  • Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients.

    abstract::To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.842981

    authors: Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

    更新日期:2014-06-01 00:00:00

  • Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

    abstract::We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260126

    authors: Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

    更新日期:2017-08-01 00:00:00

  • Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys.

    abstract::The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001663572

    authors: Cohen KA,Liu TF,Cline JM,Wagner JD,Hall PD,Frankel AE

    更新日期:2004-08-01 00:00:00

  • Contribution of flow cytometry to the diagnosis of malignant and non malignant conditions in lymph node biopsies.

    abstract::In order to assess the contribution of FC to the diagnosis of lymph node disorders we retrospectively compared the pathological and the FC diagnosis made in 118 consecutive lymph node biopsies. Pathological diagnosis included non malignant conditions (n = 43), B-cell Non Hodgkin lymphoma (NHL) (n = 30), T-cell NHL (1 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001609906

    authors: Ravoet C,Demartin S,Gerard R,Dehon M,Peny MO,Petit B,Delannoy A,Husson B

    更新日期:2004-08-01 00:00:00

  • Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia.

    abstract::There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.606938

    authors: Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

    更新日期:2012-02-01 00:00:00

  • The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells.

    abstract::Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819042000206687

    authors: Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

    更新日期:2004-08-01 00:00:00

  • Epstein-Barr virus (EBV)-induced B-cell proliferative disorder after chemotherapy in a patient with hemophagocytic lymphohistiocytosis with associated EBV-induced T-cell proliferation.

    abstract::We report a case of Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD) which developed after chemotherapy for hemophagocytic lymphohistiocytosis (HLH), who had no history of immunodeficiency or familial X-linked LPD. In HLH, the presence of EBV in T-cells was confirmed by a combination of in situ h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009058512

    authors: Suzumiya J,Ohshima K,Kanda M,Kumagawa M,Nagano M,Hirata M,Nawa Y,Tamura K,Kikuchi M

    更新日期:2000-05-01 00:00:00

  • Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.

    abstract::The recurring translocation t(1;19) (q23;p13) with TCF3-PBX1 rearrangements are uncommon in adult acute lymphoblastic leukemia (ALL), and their prognostic impact remains to be described in the era of modern chemotherapies. We investigated 427 adult patients with newly diagnosed pre-B ALL, 16 (4%) had t(1;19)(q23;p13) ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1824071

    authors: Yilmaz M,Kantarjian HM,Toruner G,Yin CC,Kanagal-Shamanna R,Cortes JE,Issa G,Short NJ,Khoury JD,Garcia-Manero G,Ravandi F,Kadia T,Konopleva M,Wierda WG,Jain N,Estrov Z,Sasaki K,Pierce S,O'Brien SM,Jabbour EJ

    更新日期:2021-01-01 00:00:00

  • Richter's syndrome in the brain first manifested as an ischaemic stroke.

    abstract::Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001638823

    authors: Robak T,Góra-Tybor J,Tybor K,Jamroziak K,Robak P,Kordek R,Rieske P,Majos A,Urbańska-Ryś H

    更新日期:2004-06-01 00:00:00

  • Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.

    abstract::Intra-vascular lymphoma is usually reported as a rare and fatal disorder. We describe here the first case of an intra-vascular lymphoma revealed by a nephrotic syndrome for which a durable remission has been obtained by 8 cycles of bi-mensual CHOP and Rituximab therapy. In this report, 18 fluorodesoxyglucose tomoscint...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001683822

    authors: Girard T,Nochy D,Montravers F,Der Sahakian G,Fior R,Galanaud P,Boué F

    更新日期:2004-08-01 00:00:00

  • Acute promyelocytic leukemia during pregnancy: a systematic analysis of outcome.

    abstract::The outcomes of acute promyelocytic leukemia (APL) in pregnancy are largely unknown. The MEDLINE database was systematically searched to obtain 43 articles with 71 patients with new-onset APL during pregnancy. Induction therapy included various regimens of all-trans retinoic acid (ATRA), cytarabine, and anthracycline ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2015.1065977

    authors: Verma V,Giri S,Manandhar S,Pathak R,Bhatt VR

    更新日期:2016-01-01 00:00:00

  • Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.

    abstract::An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.506569

    authors: Hashimoto K,Kobayashi Y,Asakura Y,Mori M,Azuma T,Maruyama D,Kim SW,Watanabe T,Tobinai K

    更新日期:2010-10-01 00:00:00

  • The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

    abstract::Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.803547

    authors: Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

    更新日期:2014-02-01 00:00:00

  • Molecular variant of hairy cell leukemia with poor prognosis.

    abstract::Hairy cell leukemia variant (HCLv), described 30 years ago, was reported to present with high disease burden and less often leukopenia, and later was reported to be resistant to purine analogs. Patients with HCLv were overrepresented among patients with HCL seeking relapsed/refractory trials. To compare clinical and m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.565841

    authors: Arons E,Kreitman RJ

    更新日期:2011-06-01 00:00:00

  • Mantle cell lymphoma: state-of-the-art management and future perspective.

    abstract::Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. Most patients present with advanced stage disease, often with extranodal dissemination, and typically pursue an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190903288514

    authors: Weigert O,Unterhalt M,Hiddemann W,Dreyling M

    更新日期:2009-12-01 00:00:00

  • Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

    abstract::High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500054350

    authors: Jabbour E,Peslin N,Arnaud P,Ferme C,Carde P,Vantelon JM,Bocaccio C,Bourhis JH,Koscielny S,Ribrag V

    更新日期:2005-06-01 00:00:00

  • Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

    abstract::Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600565057

    authors: Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

    更新日期:2006-06-01 00:00:00

  • Acute myelogenous leukemia complicated by acute necrotizing ulcerative gingivitis due to Aspergillus terreus.

    abstract::Infections caused by Aspergillus terreus are rare but have been associated with a poor outcome in immunocompromised patients due to frequent resistance to conventional antifungal therapy. This report describes a case of a woman who developed acute necrotizing ulcerative gingivitis (ANUG) due to A. terreus during induc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000060573

    authors: Khoury H,Poh CF,Williams M,Lavoie JC,Nevill TJ

    更新日期:2003-04-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study.

    abstract::Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001642846

    authors: Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

    更新日期:2004-06-01 00:00:00

  • Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

    abstract::New therapies for relapsing/refractory Hodgkin lymphoma (R/R HL) and R/R systemic anaplastic large-cell lymphoma (sALCL) have emerged. This study captured utility values for R/R HL and sALCL to support economic evaluation. Health state "vignettes" were developed describing states associated with R/R HL and sALCL: trea...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.970542

    authors: Swinburn P,Shingler S,Acaster S,Lloyd A,Bonthapally V

    更新日期:2015-06-01 00:00:00

  • Down regulation of stem cell colony formation by purified CD8 lymphocytes and CD8 conditioned medium: potential importance for bone marrow transplantation in leukemia.

    abstract::A methodology for selection of the CD8 cell subset from the peripheral blood and bone marrow mononuclear cells was developed using anti-T8 (CD8) antibody and magnetic microspheres coated with anti-mouse IgG. Following optimization of antibody:cell binding ratio and microsphere:cell ratios, CD8(+)-cells in the peripher...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209049825

    authors: Gazitt Y,He YJ

    更新日期:1992-09-01 00:00:00

  • A case of peripheral T-cell lymphoma unspecified involving subcutaneous tissue.

    abstract::A 36-year-old man presented with a 3-year-old red-brown plaque with subcutaneous nodules on his left thigh. Although a similar lesion was observed on his right thigh 3 years earlier, it spontaneously disappeared 1 year later. However, the lesion on the left thigh was growing larger. Histologically, the lesion showed a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500051406

    authors: Futagami A,Aoki M,Kawana S

    更新日期:2005-05-01 00:00:00

  • Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.

    abstract::Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep mo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1132420

    authors: Smirnikhina SA,Lavrov AV,Chelysheva EY,Adilgereeva EP,Shukhov OA,Turkina A,Kutsev SI

    更新日期:2016-07-01 00:00:00

  • Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.

    abstract::We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400013134

    authors: Chaoui D,Peffault De Latour R,Legrand O,Marie JP

    更新日期:2005-03-01 00:00:00